368 results on '"Okano N"'
Search Results
2. Association of PD-L1 and PD-L2 expression and tumor-infiltrating lymphocytes in BRAF V600E-mutated metastatic colorectal cancer: GI-SCREEN post-hoc analysis
3. Persistência do úraco
4. Design standard for railway shield tunnels in Japan
5. Combination gemcitabine plus S-1 versus gemcitabine plus cisplatin for advanced/recurrent biliary tract cancer: the FUGA-BT (JCOG1113) randomized phase III clinical trial
6. Reasonable design method of shield tunnel lining under internal water pressure
7. Effect of Sn Content on Phase Constitution and Mechanical Properties of Ti-Cr-Sn Shape Memory Alloys
8. The Potential Therapeutic Effects of Carbon Ion Beams and X-Rays on Mice with Heart Failure: Preliminary Results
9. 1244P Prognostic impact of myeloid subsets in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
10. 1217P Profiling of myeloid cells associated with prognosis in nivolumab monotherapy for advanced gastric cancer (WJOG10417GTR study)
11. 1527P GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
12. 1521P Efficacy and safety of liposomal irinotecan plus S-1 in patients with metastatic pancreatic cancer after failure of first-line gemcitabine-based chemotherapy: Result of a phase I/II study
13. Response to: The diagnosis of central retinal artery occlusion after mRNA-SARS-CoV-2 vaccination
14. Combined central retinal artery and vein occlusion shortly after mRNA-SARS-CoV-2 vaccination
15. 1203P Role of tumor markers before or during chemotherapy for poorly differentiated neuroendocrine carcinomas of the digestive system: An exploratory analysis of JCOG1213
16. 1616O Nab-paclitaxel plus gemcitabine versus modified FOLFIRINOX or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II/III trial
17. The soundness diagnosis system of plane concrete lining for railway tunnel in Japan
18. Clinical study of portal thrombosis with acute biliary infections
19. Endoscopic papillectomy for duodenal major papillary tumors
20. Early complication of endoscopic sphincterotomy—single center prospective study
21. Endoscopic treatments for pancreatic pseudocyst, abcess, and fistula
22. Influence of altered occlusal guidance on masticatory muscle activity during clenching
23. 64P Phase I/II study of nivolumab plus lenvatinib for advanced biliary tract cancer (JCOG1808/NCCH1817, SNIPE)
24. The influence of altered occlusal guidance on condylar displacement during submaximal clenching
25. Chronic intraperitoneal endotoxin treatment in rats induces resistance to d-tubocurarine, but does not produce up-regulation of acetylcholine receptors
26. The influence of altered occlusal guidance on condylar displacement
27. High frequency of circulating HBcAg-specific CD8 T cells in hepatitis B infection: a flow cytometric analysis
28. TAE FOR HCC DURING US SCANNING FOLLOWING INTRA-ARTERIAL DSA AND USANGIOGRAPHY USING CARBON DIOXIDE INSTEAD OF IODINATED CONTRAST MEDIUM
29. Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
30. Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
31. Carbon-Ion Radiotherapy for Bone and Soft Tissue Tumors; Analysis of 92 Patients at Gunma University Heavy Ion Medical Center (GHMC)
32. EP-1418 Initial results of carbon ion radiotherapy combined with S-1 for locally advanced pancreatic cancer
33. PERORAL CHOLANGIOPANCREATOSCOPY USING A NEW VIDEOSCOPE (CHF-Y0012)
34. The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer
35. Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
36. Risk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study
37. The impact of UGT1A1 genetic polymorphism on safety in unresectable pancreatic cancer patients receiving FOLFIRINOX therapy: A subset analysis of JASPAC 06 study
38. Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407)
39. FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis from the nation-wide multicenter observational study (JASPAC06)
40. First-in-man phase 1 study of TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors
41. 737P - Multicenter phase II trial of axitinib monotherapy for advanced biliary tract cancer refractory to gemcitabine-based chemotherapy
42. 108P - Biological difference of tumour mutational burden (TMB) and microsatellite instability (MSI) status in patients (pts) with somatic vs germline BRCA1/2-mutated advanced gastrointestinal (GI) cancers using cell-free DNA (cfDNA) sequencing analysis in the GOZILA study
43. Observational study of FOLFIRINOX (FFX) for unresectable/recurrent pancreatic cancer (PC) in Japanese patients (pts)(JASPAC 06): final results
44. Analysis of efficacy and prognostic factors for second-line chemotherapy in gemcitabine-refractory advanced biliary tract cancer
45. 128O Phase I study of S-trans, trans-farnesylthiosalicylic acid (salirasib), a novel oral RAS inhibitor in Japanese patients with advanced solid tumors
46. 731P - Phase II clinical trial of gemcitabine plus oxaliplatin combination therapy (GEMOX) in patients with advanced pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study)
47. 644P - The nationwide cancer genome screening project in Japan, SCRUM-Japan GI-SCREEN: Efficient identification of cancer genome alterations in advanced pancreatic cancer
48. 769TiP - Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407)
49. 760P - Risk factors for febrile neutropenia (FN) in unresectable/recurrent pancreatic cancer(PC) patients(pts) receiving FOLFIRINOX (FFX) from JASPAC06 study
50. 752P - FOLFIRINOX as second-line chemotherapy for advanced pancreatic cancer: A subset analysis from the nation-wide multicenter observational study (JASPAC06)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.